BOLT Projected Dividend Yield
Bolt Biotherapeutics Inc ( NASDAQ : BOLT )Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer.. Co.'s proprietary Boltbody™ ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gastroesophageal cancer. Co.'s second program, BDC-3042, is an agonist antibody targeting Dectin-2, an innate immune receptor found on the surface of macrophages. 20 YEAR PERFORMANCE RESULTS |
BOLT Dividend History Detail BOLT Dividend News BOLT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |